View ValuationEssbio 将来の成長Future 基準チェック /06現在、 Essbioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Water Utilities 収益成長11.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesDeclared Dividend • Mar 25Dividend increased to CL$0.37Dividend of CL$0.37 is 27% higher than last year. Ex-date: 25th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 9.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 25Full year 2025 earnings released: EPS: CL$0.001 (vs CL$0.98 in FY 2024)Full year 2025 results: EPS: CL$0.001. Revenue: CL$261.5b (up 7.4% from FY 2024). Net income: CL$33.0b (up 27% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by higher revenue.お知らせ • Mar 24Essbio S.A. announces Annual dividend, payable on May 28, 2026Essbio S.A. announced Annual dividend of CLP 0.3749 per share payable on May 28, 2026, ex-date on May 25, 2026 and record date on May 22, 2026.Valuation Update With 7 Day Price Move • Dec 17Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to CL$9.99, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 13x in the Water Utilities industry in South America. Total returns to shareholders of 5.8% over the past three years.分析記事 • Dec 16Essbio (SNSE:ESSBIO-C) Shareholders Will Want The ROCE Trajectory To ContinueIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...New Risk • Dec 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Board Change • Dec 09No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Oct 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Sep 14Second quarter 2025 earnings released: EPS: CL$0.16 (vs CL$0.13 in 2Q 2024)Second quarter 2025 results: EPS: CL$0.16 (up from CL$0.13 in 2Q 2024). Revenue: CL$60.9b (up 6.8% from 2Q 2024). Net income: CL$4.20b (up 26% from 2Q 2024). Profit margin: 6.9% (up from 5.8% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.分析記事 • Sep 04Is Essbio (SNSE:ESSBIO-C) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Sep 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Mar 27Essbio's (SNSE:ESSBIO-C) Dividend Will Be Reduced To CLP0.2943Essbio S.A. ( SNSE:ESSBIO-C ) is reducing its dividend from last year's comparable payment to CLP0.2943 on the 23rd of...Declared Dividend • Mar 27Dividend of CL$0.29 announcedShareholders will receive a dividend of CL$0.29. Ex-date: 19th May 2025 Payment date: 23rd May 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Mar 26Essbio S.A. announces Annual dividend, payable on May 23, 2025Essbio S.A. announced Annual dividend of CLP 0.2943 per share payable on May 23, 2025, ex-date on May 19, 2025 and record date on May 16, 2025.お知らせ • Mar 25Essbio S.A., Annual General Meeting, Apr 24, 2025Essbio S.A., Annual General Meeting, Apr 24, 2025. Location: av arturo prat 199, torre b 15th floor, concepcion ChileBoard Change • Jan 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Dec 24No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: CL$176.1b (up 234% from 3Q 2023). Net income: CL$22.9b (up 304% from 3Q 2023). Profit margin: 13% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue.Reported Earnings • Sep 13Second quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.22 in 2Q 2023)Second quarter 2024 results: EPS: CL$1.00. Revenue: CL$57.6b (up 1.9% from 2Q 2023). Net income: CL$3.33b (down 43% from 2Q 2023). Profit margin: 5.8% (down from 10% in 2Q 2023). The decrease in margin was driven by higher expenses.New Risk • Jun 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.分析記事 • May 21Investors Appear Satisfied With Essbio S.A.'s (SNSE:ESSBIO-C) Prospects As Shares Rocket 48%Essbio S.A. ( SNSE:ESSBIO-C ) shareholders have had their patience rewarded with a 48% share price jump in the last...Reported Earnings • May 19First quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.43 in 1Q 2023)First quarter 2024 results: EPS: CL$1.00 (up from CL$0.43 in 1Q 2023). Revenue: CL$69.2b (up 5.2% from 1Q 2023). Net income: CL$14.0b (up 22% from 1Q 2023). Profit margin: 20% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 17Investor sentiment improves as stock rises 48%After last week's 48% share price gain to CL$14.70, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 12x in the Water Utilities industry in South America. Total returns to shareholders of 59% over the past three years.Upcoming Dividend • May 10Upcoming dividend of CL$1.13 per shareEligible shareholders must have bought the stock before 17 May 2024. Payment date: 23 May 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 9.0%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.4%).Reported Earnings • Mar 17Full year 2023 earnings released: EPS: CL$2.00 (vs CL$0.27 in FY 2022)Full year 2023 results: EPS: CL$2.00 (up from CL$0.27 in FY 2022). Revenue: CL$235.2b (up 7.5% from FY 2022). Net income: CL$29.7b (up 315% from FY 2022). Profit margin: 13% (up from 3.3% in FY 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Upcoming Dividend • Dec 11Upcoming dividend of CL$0.45 per share at 8.9% yieldEligible shareholders must have bought the stock before 18 December 2023. Payment date: 21 December 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 8.9%. Lower than top quartile of Chilean dividend payers (12%). Higher than average of industry peers (3.0%).Reported Earnings • Aug 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: CL$56.8b (up 14% from 2Q 2022). Net income: CL$5.79b (up CL$8.71b from 2Q 2022). Profit margin: 10% (up from net loss in 2Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Apr 17Upcoming dividend of CL$0.27 per share at 2.3% yieldEligible shareholders must have bought the stock before 24 April 2023. Payment date: 28 April 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.3%. Lower than top quartile of Chilean dividend payers (13%). Lower than average of industry peers (3.9%).Reported Earnings • Nov 25Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CL$49.1b (up 14% from 3Q 2021). Net loss: CL$4.22b (down 228% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Board Change • Nov 16No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Sep 15We Think That There Are More Issues For Essbio (SNSE:ESSBIO-C) Than Just Sluggish EarningsEssbio S.A.'s ( SNSE:ESSBIO-C ) recent weak earnings report didn't cause a big stock movement. However, we believe that...Reported Earnings • Sep 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CL$49.9b (up 15% from 2Q 2021). Net loss: CL$2.92b (down 201% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.Reported Earnings • May 15First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: CL$59.7b (up 17% from 1Q 2021). Net income: CL$11.7b (up 18% from 1Q 2021). Profit margin: 20% (in line with 1Q 2021).Upcoming Dividend • May 13Upcoming dividend of CL$0.70 per shareEligible shareholders must have bought the stock before 20 May 2022. Payment date: 26 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.9%. Lower than top quartile of Chilean dividend payers (11%). Higher than average of industry peers (3.7%).Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Mar 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: CL$189.8b (up 9.2% from FY 2020). Net income: CL$18.5b (down 11% from FY 2020). Profit margin: 9.7% (down from 12% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Dec 04Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: CL$43.4b (up 14% from 3Q 2020). Net income: CL$3.31b (up 54% from 3Q 2020). Profit margin: 7.6% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.Reported Earnings • Sep 12Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CL$43.5b (up 8.0% from 2Q 2020). Net income: CL$2.88b (down 24% from 2Q 2020). Profit margin: 6.6% (down from 9.5% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.分析記事 • May 30Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 20First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CL$51.3b (up 4.1% from 1Q 2020). Net income: CL$9.87b (down 6.3% from 1Q 2020). Profit margin: 19% (down from 21% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 07Upcoming dividend of CL$0.24 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 19 May 2021. Trailing yield: 3.9%. Lower than top quartile of Chilean dividend payers (6.1%). Higher than average of industry peers (3.1%).分析記事 • Mar 29A Look At The Intrinsic Value Of Essbio S.A. (SNSE:ESSBIO-C)How far off is Essbio S.A. ( SNSE:ESSBIO-C ) from its intrinsic value? Using the most recent financial data, we'll take...Reported Earnings • Mar 29Full year 2020 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CL$174.4b (up 3.1% from FY 2019). Net income: CL$20.8b (up 1.4% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 7% per year.分析記事 • Mar 09Should You Be Impressed By Essbio's (SNSE:ESSBIO-C) Returns on Capital?If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • Feb 15Here's Why Essbio (SNSE:ESSBIO-C) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jan 04Should Essbio S.A. (SNSE:ESSBIO-C) Focus On Improving This Fundamental Metric?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...分析記事 • Dec 08Has Essbio (SNSE:ESSBIO-C) Got What It Takes To Become A Multi-Bagger?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...分析記事 • Nov 17Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Essbio は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測SNSE:ESSBIO-C - アナリストの将来予測と過去の財務データ ( )CLP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025255,89033,05032,626110,644N/A9/30/2025250,91728,32127,212107,457N/A6/30/2025248,90428,17426,090104,966N/A3/31/2025247,00927,30230,065106,732N/A12/31/2024243,36325,94725,319102,482N/A9/30/2024240,04626,61024,427102,443N/A6/30/2024237,54729,78129,218106,169N/A3/31/2024237,00632,24428,410110,127N/A12/31/2023233,76829,68429,485108,050N/A9/30/2023235,75525,52633,728109,236N/A6/30/2023231,95515,63530,957105,102N/A3/31/2023225,1546,92631,704100,169N/A12/31/2022218,8557,14930,77294,961N/A9/30/2022209,5376,94229,13987,647N/A6/30/2022203,86114,46932,46087,908N/A3/31/2022197,45520,26727,64181,660N/A12/31/2021188,89818,46627,04877,548N/A9/30/2021183,49220,34724,19574,217N/A6/30/2021178,32719,19521,98270,875N/A3/31/2021175,47220,12720,84468,509N/A12/31/2020173,77720,78617,13369,802N/A9/30/2020171,48321,10723,50179,813N/A6/30/2020170,23021,04622,72375,818N/A3/31/2020169,93520,09426,76778,149N/A12/31/2019169,19320,50831,72077,855N/A9/30/2019168,47721,139N/A73,913N/A6/30/2019167,46320,702N/A74,630N/A3/31/2019163,75820,694N/A75,230N/A12/31/2018159,27219,259N/A68,611N/A9/30/2018156,18517,720N/A60,638N/A6/30/2018153,70119,387N/A56,947N/A3/31/2018151,90422,260N/A50,551N/A12/31/2017149,56425,132N/A50,057N/A9/30/2017149,29827,874N/A46,367N/A6/30/2017148,07026,884N/A47,472N/A3/31/2017146,71223,866N/A45,691N/A12/31/2016147,73123,351N/A44,956N/A9/30/2016141,45127,218N/A46,721N/A6/30/2016141,81326,833N/A47,332N/A3/31/2016142,40626,295N/A51,453N/A12/31/2015140,12225,176N/A53,715N/A9/30/2015144,23316,276N/A45,469N/A6/30/2015141,44716,099N/A43,728N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ESSBIO-Cの予測収益成長が 貯蓄率 ( 5.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ESSBIO-Cの収益がCL市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ESSBIO-Cの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ESSBIO-Cの収益がCL市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ESSBIO-Cの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ESSBIO-Cの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YUtilities 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 07:21終値2026/05/06 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Essbio S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Declared Dividend • Mar 25Dividend increased to CL$0.37Dividend of CL$0.37 is 27% higher than last year. Ex-date: 25th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 9.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 25Full year 2025 earnings released: EPS: CL$0.001 (vs CL$0.98 in FY 2024)Full year 2025 results: EPS: CL$0.001. Revenue: CL$261.5b (up 7.4% from FY 2024). Net income: CL$33.0b (up 27% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by higher revenue.
お知らせ • Mar 24Essbio S.A. announces Annual dividend, payable on May 28, 2026Essbio S.A. announced Annual dividend of CLP 0.3749 per share payable on May 28, 2026, ex-date on May 25, 2026 and record date on May 22, 2026.
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to CL$9.99, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 13x in the Water Utilities industry in South America. Total returns to shareholders of 5.8% over the past three years.
分析記事 • Dec 16Essbio (SNSE:ESSBIO-C) Shareholders Will Want The ROCE Trajectory To ContinueIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
New Risk • Dec 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Board Change • Dec 09No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Oct 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 14Second quarter 2025 earnings released: EPS: CL$0.16 (vs CL$0.13 in 2Q 2024)Second quarter 2025 results: EPS: CL$0.16 (up from CL$0.13 in 2Q 2024). Revenue: CL$60.9b (up 6.8% from 2Q 2024). Net income: CL$4.20b (up 26% from 2Q 2024). Profit margin: 6.9% (up from 5.8% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
分析記事 • Sep 04Is Essbio (SNSE:ESSBIO-C) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Sep 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Mar 27Essbio's (SNSE:ESSBIO-C) Dividend Will Be Reduced To CLP0.2943Essbio S.A. ( SNSE:ESSBIO-C ) is reducing its dividend from last year's comparable payment to CLP0.2943 on the 23rd of...
Declared Dividend • Mar 27Dividend of CL$0.29 announcedShareholders will receive a dividend of CL$0.29. Ex-date: 19th May 2025 Payment date: 23rd May 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 26Essbio S.A. announces Annual dividend, payable on May 23, 2025Essbio S.A. announced Annual dividend of CLP 0.2943 per share payable on May 23, 2025, ex-date on May 19, 2025 and record date on May 16, 2025.
お知らせ • Mar 25Essbio S.A., Annual General Meeting, Apr 24, 2025Essbio S.A., Annual General Meeting, Apr 24, 2025. Location: av arturo prat 199, torre b 15th floor, concepcion Chile
Board Change • Jan 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Dec 24No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: CL$176.1b (up 234% from 3Q 2023). Net income: CL$22.9b (up 304% from 3Q 2023). Profit margin: 13% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue.
Reported Earnings • Sep 13Second quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.22 in 2Q 2023)Second quarter 2024 results: EPS: CL$1.00. Revenue: CL$57.6b (up 1.9% from 2Q 2023). Net income: CL$3.33b (down 43% from 2Q 2023). Profit margin: 5.8% (down from 10% in 2Q 2023). The decrease in margin was driven by higher expenses.
New Risk • Jun 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
分析記事 • May 21Investors Appear Satisfied With Essbio S.A.'s (SNSE:ESSBIO-C) Prospects As Shares Rocket 48%Essbio S.A. ( SNSE:ESSBIO-C ) shareholders have had their patience rewarded with a 48% share price jump in the last...
Reported Earnings • May 19First quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.43 in 1Q 2023)First quarter 2024 results: EPS: CL$1.00 (up from CL$0.43 in 1Q 2023). Revenue: CL$69.2b (up 5.2% from 1Q 2023). Net income: CL$14.0b (up 22% from 1Q 2023). Profit margin: 20% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 17Investor sentiment improves as stock rises 48%After last week's 48% share price gain to CL$14.70, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 12x in the Water Utilities industry in South America. Total returns to shareholders of 59% over the past three years.
Upcoming Dividend • May 10Upcoming dividend of CL$1.13 per shareEligible shareholders must have bought the stock before 17 May 2024. Payment date: 23 May 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 9.0%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.4%).
Reported Earnings • Mar 17Full year 2023 earnings released: EPS: CL$2.00 (vs CL$0.27 in FY 2022)Full year 2023 results: EPS: CL$2.00 (up from CL$0.27 in FY 2022). Revenue: CL$235.2b (up 7.5% from FY 2022). Net income: CL$29.7b (up 315% from FY 2022). Profit margin: 13% (up from 3.3% in FY 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 11Upcoming dividend of CL$0.45 per share at 8.9% yieldEligible shareholders must have bought the stock before 18 December 2023. Payment date: 21 December 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 8.9%. Lower than top quartile of Chilean dividend payers (12%). Higher than average of industry peers (3.0%).
Reported Earnings • Aug 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: CL$56.8b (up 14% from 2Q 2022). Net income: CL$5.79b (up CL$8.71b from 2Q 2022). Profit margin: 10% (up from net loss in 2Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Apr 17Upcoming dividend of CL$0.27 per share at 2.3% yieldEligible shareholders must have bought the stock before 24 April 2023. Payment date: 28 April 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.3%. Lower than top quartile of Chilean dividend payers (13%). Lower than average of industry peers (3.9%).
Reported Earnings • Nov 25Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CL$49.1b (up 14% from 3Q 2021). Net loss: CL$4.22b (down 228% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Board Change • Nov 16No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Sep 15We Think That There Are More Issues For Essbio (SNSE:ESSBIO-C) Than Just Sluggish EarningsEssbio S.A.'s ( SNSE:ESSBIO-C ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
Reported Earnings • Sep 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CL$49.9b (up 15% from 2Q 2021). Net loss: CL$2.92b (down 201% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.
Reported Earnings • May 15First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: CL$59.7b (up 17% from 1Q 2021). Net income: CL$11.7b (up 18% from 1Q 2021). Profit margin: 20% (in line with 1Q 2021).
Upcoming Dividend • May 13Upcoming dividend of CL$0.70 per shareEligible shareholders must have bought the stock before 20 May 2022. Payment date: 26 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.9%. Lower than top quartile of Chilean dividend payers (11%). Higher than average of industry peers (3.7%).
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: CL$189.8b (up 9.2% from FY 2020). Net income: CL$18.5b (down 11% from FY 2020). Profit margin: 9.7% (down from 12% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Dec 04Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: CL$43.4b (up 14% from 3Q 2020). Net income: CL$3.31b (up 54% from 3Q 2020). Profit margin: 7.6% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.
Reported Earnings • Sep 12Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CL$43.5b (up 8.0% from 2Q 2020). Net income: CL$2.88b (down 24% from 2Q 2020). Profit margin: 6.6% (down from 9.5% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
分析記事 • May 30Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 20First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CL$51.3b (up 4.1% from 1Q 2020). Net income: CL$9.87b (down 6.3% from 1Q 2020). Profit margin: 19% (down from 21% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 07Upcoming dividend of CL$0.24 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 19 May 2021. Trailing yield: 3.9%. Lower than top quartile of Chilean dividend payers (6.1%). Higher than average of industry peers (3.1%).
分析記事 • Mar 29A Look At The Intrinsic Value Of Essbio S.A. (SNSE:ESSBIO-C)How far off is Essbio S.A. ( SNSE:ESSBIO-C ) from its intrinsic value? Using the most recent financial data, we'll take...
Reported Earnings • Mar 29Full year 2020 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CL$174.4b (up 3.1% from FY 2019). Net income: CL$20.8b (up 1.4% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 7% per year.
分析記事 • Mar 09Should You Be Impressed By Essbio's (SNSE:ESSBIO-C) Returns on Capital?If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
分析記事 • Feb 15Here's Why Essbio (SNSE:ESSBIO-C) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jan 04Should Essbio S.A. (SNSE:ESSBIO-C) Focus On Improving This Fundamental Metric?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
分析記事 • Dec 08Has Essbio (SNSE:ESSBIO-C) Got What It Takes To Become A Multi-Bagger?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...
分析記事 • Nov 17Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...